Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells $225,370.00 in Stock

Key Points

• CEO Renee Gala sold 1,000 shares for $225,370 under a pre-arranged Rule 10b5-1 plan, retaining 140,394 shares after the transaction.
• Jazz Pharmaceuticals beat quarterly expectations, reporting $1.24 billion in revenue versus $1.21 billion forecast and EPS of -$3.88 versus -$4.03 expected; revenue grew 10.4% year over year.
• Analyst sentiment remained broadly positive: the stock had a “Moderate Buy” consensus rating and an average price target of $293.45, while shares fell 3.1% in Thursday trading.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Get Free Report) CEO Renee Gala sold 1,000 shares of the firm's stock in a transaction dated Tuesday, November 3rd. The stock was sold at an average price of $225.37, for a total transaction of $225,370.00. Following the completion of the transaction, the chief executive officer directly owned 140,394 shares in the company, valued at $31,640,595.78. This represents a 0.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Down 3.1%

JAZZ stock traded down $7.34 during trading on Thursday, hitting $227.32. 670,555 shares of the company's stock traded hands, compared to its average volume of 933,464. The firm has a market capitalization of $14.59 billion, a P/E ratio of 77.32, a PEG ratio of 0.46 and a beta of 0.38. Jazz Pharmaceuticals PLC has a 1 year low of $128.80 and a 1 year high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.82 and a debt-to-equity ratio of 1.09. The business has a fifty day simple moving average of $230.15 and a two-hundred day simple moving average of $217.11.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, topping analysts' consensus estimates of ($4.03) by $0.15. The firm had revenue of $1.24 billion during the quarter, compared to analysts' expectations of $1.21 billion. Jazz Pharmaceuticals had a return on equity of 16.88% and a net margin of 4.37%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm earned $8.13 EPS. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 10.84 EPS for the current year.

Analyst Ratings Changes

JAZZ has been the topic of several analyst reports. Deutsche Bank Aktiengesellschaft lifted their price target on Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a "buy" rating in a report on Wednesday, August 26th. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, August 26th. Barclays raised their price objective on shares of Jazz Pharmaceuticals from $271.00 to $275.00 and gave the stock an "overweight" rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $300.00 to $310.00 and gave the stock an "overweight" rating in a research note on Tuesday. Finally, Weiss Ratings lowered shares of Jazz Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $293.45.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. USA Financial Formulas acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Pension & Wealth Management Advisors Inc. acquired a new position in shares of Jazz Pharmaceuticals during the third quarter worth about $32,000. Ameritas Advisory Services LLC purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth approximately $47,000. Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth approximately $61,000. Finally, Elevation Wealth Partners LLC raised its holdings in Jazz Pharmaceuticals by 156.4% in the third quarter. Elevation Wealth Partners LLC now owns 259 shares of the specialty pharmaceutical company's stock valued at $60,000 after acquiring an additional 158 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz reported third-quarter revenue of $1.24 billion, above expectations of $1.21 billion, and EPS that also beat consensus. Revenue rose 10.4% year over year. The company also raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, according to the earnings coverage. Earnings coverage
• Positive Sentiment: Analyst sentiment was supportive after the results: RBC and Morgan Stanley reportedly saw further upside, while Barclays and JPMorgan raised their price targets. RBC analyst outlook Barclays price target Morgan Stanley outlook JPMorgan price target
• Neutral Sentiment: Director Bruce Cozadd sold 6,000 shares for about $1.30 million under a pre-arranged Rule 10b5-1 plan. The sale reduced his holdings by 1.73%, but he retained 339,875 shares. Director sale details

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.

Jazz's sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.